IR News

by Category

Corporate

Oct. 03, 2022 (PDF/601KB)Corporate

Sumitomo Pharma and Sumitovant Biopharma Announce Offer to Acquire Outstanding Shares of Myovant Sciences
Sep. 27, 2022 (PDF/183KB)Corporate

Appeal of Inter Partes Review (IPR) USPTO Decision on the Method of Use Patent for LATUDA
Sep. 02, 2022 (PDF/585KB)Corporate

Sumitomo Pharma Announces Personnel Changes
Jul. 13, 2022 (PDF/272KB)Corporate

Notice of Relocation of Tokyo Head Office
Jun. 29, 2022 (PDF/146KB)Corporate

(Update on Disclosed Matter) Notice of Establishment of Holding Company in China
May 13, 2022 (PDF/171KB)Corporate

Sumitomo Pharma Announces Changes in Board of Directors and Audit & Supervisory Board
Apr. 22, 2022 (PDF/148KB)Corporate

Sumitomo Pharma Builds Cell-Processing Center in U.S.
Apr. 01, 2022 (PDF/197KB)Corporate

Notice of Change of the Trade Name
Mar. 30, 2022 (PDF/103KB)Corporate

Notice of Establishment of Holding Company in China
Mar. 11, 2022 (PDF/123KB)Corporate

Sumitomo Dainippon Pharma Announces Additional Investment in Aikomi Ltd.
Mar. 02, 2022 (PDF/139KB)Corporate

Sumitomo Dainippon Pharma Announces Changes in Executive Officers Including Representative Director, Organizational Realignment and Personnel Changes
Dec. 09, 2021 (PDF/103KB)Corporate

Notice of the Decision of USPTO on Inter Partes Review (IPR) Proceeding for Method of Use Patent of LATUDA
Dec. 07, 2021 (PDF/118KB)Corporate

Sumitomo Dainippon Pharma Establishes a Local Subsidiary in Malaysia
Dec. 03, 2021 (PDF/78KB)Corporate

Notice of Application for Selection of "Prime Market" in Tokyo Stock Exchange New Market Segments
Sep. 02, 2021 (PDF/99KB)Corporate

Sumitomo Dainippon Pharma Opens a Representative Office in Vietnam
Sep. 02, 2021 (PDF/78KB)Corporate

Sumitomo Dainippon Pharma Announces Personnel Changes
Aug. 19, 2021 (PDF/83KB)Corporate

Sumitomo Dainippon Pharma Announces Transfer of Shares of its Indirectly-Owned Subsidiary in Europe
Jun. 03, 2021 (PDF/74KB)Corporate

Comments Regarding Media Article on Our Company
May 12, 2021 (PDF/140KB)Corporate

Notice of Change of Trade Name and Partial Amendment to Articles of Incorporation
May 12, 2021 (PDF/439KB)Corporate

Notice of Relocation of Tokyo Head Office
May 12, 2021 (PDF/105KB)Corporate

Sumitomo Dainippon Pharma Announces Changes in Board of Directors and Audit & Supervisory Board
May 06, 2021 (PDF/83KB)Corporate

Consolidated Subsidiary Enzyvant Transfers its RVT-801, an Investigational Therapy for Farber Disease, to Aceragen
May 06, 2021 (PDF/105KB)Corporate

Sumitomo Dainippon Pharma Announces Investment in Special Purpose Acquisition Company Combining with Roivant Sciences
Mar. 30, 2021 (PDF/85KB)Corporate

Sumitovant Completes the "Going Private" Transaction with Our Consolidated Subsidiary, Urovant
Mar. 02, 2021 (PDF/131KB)Corporate

Sumitomo Dainippon Pharma Announces Organizational Realignment and Changes in the Positions Assumed by Executive Officers and Other Key Positions
Feb. 26, 2021 (PDF/86KB)Corporate

Sumitomo Dainippon Pharma Announces Changes of Representative Directors and Executive Officers
Feb. 01, 2021 (PDF/106KB)Corporate

Sumitomo Dainippon Pharma Announces Investment in a Venture Capital Fund
Nov. 13, 2020 (PDF/82KB)Corporate

Sumitovant Enters into an Agreement for "Going Private" Transaction with its U.S. Subsidiary Urovant
Oct. 08, 2020 (PDF/169KB)Corporate

Sumitomo Chemical and Sumitomo Dainippon Pharma Announce Establishment and Inception of Operations of a Joint Venture Company for CDMO Business in the field of Regenerative Medicine and Cell Therapy
Oct. 08, 2020 (PDF/29KB)Corporate

Urovant Sciences Announces Co-Promotion Agreement for Vibegron with Sunovion Pharmaceuticals
Sep. 23, 2020 (PDF/98KB)Corporate

Sumitomo Dainippon Pharma Establishes a Subsidiary in Taiwan
Sep. 17, 2020 (PDF/80KB)Corporate

Sumitomo Dainippon Pharma Announces Change in Executive Officer
Sep. 01, 2020 (PDF/123KB)Corporate

Sumitomo Dainippon Pharma Announces Organizational Realignment and Change in Executive Officer
Aug. 06, 2020 (PDF/52KB)Corporate

Myovant Sciences Announces Further Financing Support from Sumitomo Dainippon Pharma and Commercial Collaboration with Sunovion Pharmaceuticals
Jun. 26, 2020 (PDF/81KB)Corporate

Sumitomo Dainippon Pharma Announces Transfer of a Fixed Asset
Jun. 22, 2020 (PDF/157KB)Corporate

Notice of the Filing of a Petition for Inter Partes Review (IPR) to USPTO for Method of Use Patent of LATUDA
Jun. 19, 2020 (PDF/27KB)Corporate

Urovant Sciences Announces Collaboration with Sunovion Pharmaceuticals
May 29, 2020 (PDF/109KB)Corporate

Sumitomo Dainippon Pharma Announces Merger of US consolidated subsidiaries
May 13, 2020 (PDF/80KB)Corporate

Sumitomo Dainippon Pharma Announces Change in Board of Directors
Mar. 18, 2020 (PDF/83KB)Corporate

Sumitomo Dainippon Pharma Announces Change in Executive Officer and Other Key Position
Mar. 03, 2020 (PDF/122KB)Corporate

Sumitomo Dainippon Pharma Announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Mar. 02, 2020 (PDF/139KB)Corporate

Sumitomo Dainippon Pharma Announces Investment in MPM Oncology Innovations Fund
Jan. 17, 2020 (PDF/97KB)Corporate

Sumitomo Dainippon Pharma announces Personnel Change
Jan. 09, 2020 (PDF/228KB)Corporate

Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life‐Saving Treatment for Post‐Lung Transplant Patients to the Altavant Pipeline
Dec. 28, 2019 (PDF/115KB)Corporate

Sumitomo Dainippon Pharma Completes the Formation of the Strategic Alliance with Roivant Sciences
Nov. 27, 2019 (PDF/114KB)Corporate

Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officer and Other Key Positions
Nov. 08, 2019Corporate

Posted Video of Investors Meeting Presentation for Q2 FY2019 (April 1 to September 30, 2019) ／Definitive Agreement for Strategic Alliance with Roivant Sciences [Webcast]
Oct. 31, 2019 (PDF/1,705KB)Corporate

Investors Meeting Presentation for Q2 FY2019 (April 1 to September 30, 2019) ／Definitive Agreement for Strategic Alliance with Roivant Sciences
Oct. 31, 2019 (PDF/1,557KB)Corporate

Press Conference Presentation for Definitive Agreement for Strategic Alliance with Roivant Sciences
Oct. 31, 2019 (PDF/186KB)Corporate

Sumitomo Dainippon Pharma and Roivant Sciences Sign a Definitive Agreement for a Strategic Alliance
Oct. 31, 2019 (PDF/103KB)Corporate

【Joint press release】Sumitomo Dainippon Pharma and Roivant Sciences Sign Definitive Agreement for Strategic Alliance
Oct. 18, 2019 (PDF/237KB)Corporate

Sumitomo Dainippon Pharma announces Change in Executive Officer
Oct. 17, 2019 (PDF/94KB)Corporate

Comments on Acquisition Proposal to Australian Stem Cell and Regenerative Medicine Company
Sep. 12, 2019Corporate

Posted Conference Call for Memorandum of Understanding for Strategic Alliance with Roivant Sciences [Webcast]
Sep. 06, 2019 (PDF/477KB)Corporate

Presentation Material（Memorandum of Understanding for Strategic Alliance with Roivant Sciences）
Sep. 06, 2019 (PDF/269KB)Corporate

Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding for a Strategic Alliance
Sep. 06, 2019 (PDF/224KB)Corporate

【Joint press release】Sumitomo Dainippon Pharma and Roivant Sciences Enter into a Memorandum of Understanding to Create Broad Strategic Alliance to Deliver Promising New Medicines to Patients
Aug. 29, 2019 (PDF/244KB)Corporate

Sumitomo Dainippon Pharma announces Investment in a Venture Capital Fund
Jul. 25, 2019 (PDF/109KB)Corporate

Sumitomo Dainippon Pharma to Enter Into an Investment Agreement with Drawbridge Health
Jul. 19, 2019 (PDF/80KB)Corporate

Comments on Announcement by Australian Stem Cell and Regenerative Medicine Company
Jun. 17, 2019 (PDF/241KB)Corporate

Sumitomo Dainippon Pharma announces Personnel Changes
May 10, 2019 (PDF/217KB)Corporate

Sumitomo Dainippon Pharma announces Changes in Board of Directors
May 08, 2019 (PDF/128KB)Corporate

Sumitomo Dainippon Pharma to Open a New Office for its Regenerative Medicine/Cell Therapy Business in San Diego, U.S.
Apr. 26, 2019 (PDF/56KB)Corporate

Sumitomo Dainippon Pharma Announces Revision to its Dividend Forecast for the Year Ending March 2019
Mar. 28, 2019 (PDF/118KB)Corporate

AlphaNavi Pharma Established as a Carve-Out Business Venture from Sumitomo Dainippon Pharma with Investment
Mar. 04, 2019 (PDF/172KB)Corporate

Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Mar. 04, 2019 (PDF/94KB)Corporate

Sumitomo Dainippon Pharma Expands Roles and Responsibilities of Subsidiary in Singapore and Establishes Subsidiary in Thailand
Dec. 28, 2018 (PDF/72KB)Corporate

Correction to "Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S."
Dec. 25, 2018 (PDF/103KB)Corporate

Merger of DS Pharma Biomedical and DS Pharma Promo
Dec. 05, 2018 (PDF/39KB)Corporate

Sumitomo Dainippon Pharma Announces Resolution of Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S.
Nov. 27, 2018 (PDF/40KB)Corporate

Sumitomo Dainippon Pharma Announces Resolution of Disputes under Consolidated Patent Infringement Lawsuit Regarding ANDAs for LATUDA in the U.S. (Partial correction on December 28, 2018)
Sep. 03, 2018 (PDF/129KB)Corporate

Sumitomo Dainippon Pharma announces personnel changes
Jun. 15, 2018 (PDF/127KB)Corporate

Sumitomo Dainippon Pharma announces personnel changes
May 11, 2018 (PDF/48KB)Corporate

Sumitomo Dainippon Pharma announces Changes in Board of Directors, Audit & Supervisory Board and Other Key Positions
Apr. 18, 2018 (PDF/101KB)Corporate

Sumitomo Dainippon Pharma Announces U.S. Appellate Court Decision on Substance Patent Infringement Lawsuit Regarding LATUDA
Mar. 27, 2018 (PDF/128KB)Corporate

Establishment of Shared Service Subsidiary
Mar. 01, 2018 (PDF/74KB)Corporate

Updated Regenerative Medicine/Cell Therapy Business Plan
Mar. 01, 2018 (PDF/264KB)Corporate

Sumitomo Dainippon Pharma Completes Manufacturing Plant for Regenerative Medicine & Cell Therapy
Mar. 01, 2018 (PDF/175KB)Corporate

Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Feb. 24, 2018 (PDF/140KB)Corporate

SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Additional Patent Infringement Lawsuit Regarding LATUDA in the United States
Feb. 23, 2018 (PDF/254KB)Corporate

Sumitomo Dainippon Pharma Appoints Hiroshi Nomura as President and CEO
Feb. 14, 2018 (PDF/89KB)Corporate

SUMITOMO DAINIPPON PHARMA CO., LTD. Filed Patent Infringement Lawsuits Regarding LATUDA in the United States
Jan. 30, 2018 (PDF/107KB)Corporate

Sumitomo Dainippon Pharma Announces Revision to its Dividend Forecast for the Year Ending March 2018
Jan. 05, 2018 (PDF/141KB)Corporate

Sumitomo Dainippon Pharma announces Personnel Change
Dec. 25, 2017 (PDF/215KB)Corporate

Sumitomo Dainippon Pharma Announces the Results of Its Early Retirement Program Offer for Japanese Employees
Dec. 21, 2017 (PDF/58KB)Corporate

Dissolution of Create Vaccine Company, Ltd.
Dec. 14, 2017 (PDF/128KB)Corporate

Sumitomo Dainippon Pharma announces Organizational Realignment and Personnel Change
Dec. 14, 2017 (PDF/100KB)Corporate

Establishment of Bioscience Research Laboratory and Transfer of Functions of Genomic Science Laboratories
Sep. 27, 2017 (PDF/223KB)Corporate

Sumitomo Dainippon Pharma announces offering an Early Retirement Program to Japanese Employees
Sep. 01, 2017 (PDF/146KB)Corporate

Sumitomo Dainippon Pharma announces Organizational Realignment and Changes in Executive Officers and Other Key Positions
Jul. 25, 2017 (PDF/105KB)Corporate

Sumitomo Dainippon Pharma Announces Investment in DEFTA Healthcare Technologies, L.P.
Jul. 14, 2017 (PDF/252KB)Corporate

Sunovion Enters Agreement to Divest Asthma and Allergy Products to Covis Pharma
Jul. 04, 2017 (PDF/49KB)Corporate

Sumitomo Dainippon Pharma Announces Change in Name of Consolidated Subsidiary Based in U.S.
Jun. 16, 2017 (PDF/125KB)Corporate

Sumitomo Dainippon Pharma announces personnel change
May 18, 2017 (PDF/124KB)Corporate

Sumitomo Dainippon Pharma announces personnel change
May 11, 2017 (PDF/55KB)Corporate

Sumitomo Dainippon Pharma announces Changes in Board of Directors and Audit & Supervisory Board
May 11, 2017 (PDF/122KB)Corporate

Sumitomo Dainippon Pharma Announces Dividends (Including Special Dividends) of Surplus
May 08, 2017 (PDF/118KB)Corporate

Sumitomo Dainippon Pharma announces personnel change
Mar. 29, 2017 (PDF/61KB)Corporate

Sumitomo Dainippon Pharma announces Changes in Executive Officers
Feb. 24, 2017 (PDF/29KB)Corporate

Sumitomo Dainippon Pharma announces Changes of Representative Directorsand Executive Officers
Jan. 26, 2017 (PDF/63KB)Corporate

Sumitomo Dainippon Pharma Completes Acquisition of Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
Dec. 26, 2016Corporate

Posted Conference Call for Acquisition of Tolero Pharmaceuticals, Inc. [Webcast]
Dec. 21, 2016 (PDF/686KB)Corporate

Teleconference Material (Acquisition of Tolero Pharmaceuticals, Inc.)
Dec. 21, 2016 (PDF/153KB)Corporate

Sumitomo Dainippon Pharma to Acquire Tolero Pharmaceuticals, Inc. (US Biotechnology Company)
Dec. 21, 2016 (PDF/98KB)Corporate

Sumitomo Dainippon Pharma Announces Merger of US consolidated subsidiaries
Oct. 27, 2016 (PDF/77KB)Corporate

Sumitomo Dainippon Pharma Announces the Establishment of a Subsidiary for Promotion of Authorized Generics and others
Oct. 24, 2016 (PDF/84KB)Corporate

Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion Pharmaceuticals Completes Acquisition of Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
Oct. 21, 2016 (PDF/112KB)Corporate

Sumitomo Dainippon Pharma Announces the Results of Its Early Retirement Program Offer for Japanese Employees
Sep. 01, 2016 (PDF/102KB)Corporate

Sumitomo Dainippon Pharma's U.S. Subsidiary Sunovion to Acquire Cynapsus Therapeutics Inc. (Canadian Specialty Central Nervous System Biotechnology Company)
Aug. 30, 2016 (PDF/132KB)Corporate

Sumitomo Dainippon Pharma announces offering an Early Retirement Program to Japanese Employees and Reduction in Executive Remuneration
May 11, 2016 (PDF/115KB)Corporate

Sumitomo Dainippon Pharma announces Change of Directors
Oct. 01, 2015Corporate

Posted Basic Policy on Corporate Governance
Apr. 24, 2015 (PDF/130KB)Corporate

Sumitomo Dainippon Pharma Revises Its Basic Policy on Internal Control System
Jan. 14, 2015 (PDF/165KB)Corporate

Sunovion Pharmaceuticals Inc. Files Patent Infringement Lawsuits Regarding Latuda
Dec. 26, 2014 (PDF/165KB)Corporate

Sumitomo Dainippon Pharma Announces Reorganization of Production Sites
Oct. 30, 2014 (PDF/168KB)Corporate

Sumitomo Dainippon Pharma Announces Transfer of a Fixed Asset
Oct. 01, 2014 (PDF/88KB)Corporate

Sunovion Pharmaceuticals Inc. to Divest Xopenex (levalbuterol HCI) Inhalation Solution (IS) to Akorn, Inc.
Aug. 29, 2014 (PDF/113KB)Corporate

Sumitomo Dainippon Pharma Announces Transfer of Certain Fixed Assets
Jul. 23, 2014 (PDF/40KB)Corporate

Sumitomo Dainippon Pharma announces Investment in a New Venture Capital Fund
Jun. 30, 2014 (PDF/215KB)Corporate

Transfer of Marketing Rights for "Inteban", "Catlep" and "Drenison"
Jun. 19, 2014 (PDF/181KB)Corporate

Sumitomo Dainippon Pharma announces Change of the Company’s English trade name
May 22, 2014 (PDF/174KB)Corporate

Joint Investment into Create Vaccine Company, Ltd.
May 21, 2014 (PDF/183KB)Corporate

Dainippon Sumitomo Pharma Announces Change of the Company’s English trade name and Partial Amendments to Its Articles of Incorporation
May 08, 2014 (PDF/111KB)Corporate

Dainippon Sumitomo Pharma announces Change of Directors
Mar. 06, 2014 (PDF/53KB)Corporate

Healios and Dainippon Sumitomo Pharma establish a joint venture company for regenerative medicine and cell therapy business
Feb. 28, 2014 (PDF/225KB)Corporate

Transfer of Marketing Rights for "Inteban", "Catlep" and "Drenison"
Nov. 08, 2013 (PDF/43KB)Corporate

A Basic Agreement Reached for Joint Development of New TB Vaccines
Oct. 09, 2013 (PDF/141KB)Corporate

Dainippon Sumitomo Pharma to Establish an Anti-Cancer Drugs Sales Company in the U.S.
May 09, 2013 (PDF/66KB)Corporate

Change of Directors and Audit & Supervisory Board Members
Mar. 28, 2013 (PDF/40KB)Corporate

Retina Institute Japan and Dainippon Sumitomo Pharma form a capital alliance towards the development of Nobel Prize winning iPS cell technology
Sep. 06, 2012 (PDF/33KB)Corporate

Sunovion Pharmaceuticals Inc. Completes Acquisition of Elevation Pharmaceuticals, Inc.
Aug. 31, 2012 (PDF/59KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd.'s U.S. Subsidiary Sunovion Pharmaceuticals Inc. to Acquire Elevation Pharmaceuticals, Inc. (US Biopharmaceutical Company)
May 25, 2012 (PDF/22KB)Corporate

Sunovion Pharmaceuticals settles dispute on BROVANA patent litigation
May 10, 2012 (PDF/46KB)Corporate

Change of Members of Board of Directors and Executive Officer
Apr. 25, 2012 (PDF/31KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Boston Biomedical, Inc. (US Biotechnology Company)
Feb. 29, 2012 (PDF/365KB)Corporate

Presentation Material (Acquisition of Boston Biomedical Inc.)
Feb. 29, 2012 (PDF/58KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. to Acquire Boston Biomedical Inc. (US Biotechnology Company)
Feb. 23, 2012 (PDF/55KB)Corporate

Change of Representative Directors and Executive Officers
May 11, 2011 (PDF/53KB)Corporate

Change of Members of Board of Directors, Corporate Auditors and Executive Officers
May 11, 2011 (PDF/51KB)Corporate

Change of Representative Directors
Mar. 01, 2011 (PDF/52KB)Corporate

Execution of the definitive agreement for the assignment of "Radarcirc" business
Dec. 14, 2010 (PDF/68KB)Corporate

Merger of the Chinese subsidiaries completed
Oct. 13, 2010 (PDF/68KB)Corporate

SUNOVION PHARMACEUTICALS INC. ANNOUNCES COMPANY NAME CHANGE
Jul. 16, 2010 (PDF/63KB)Corporate

SEPRACOR INC. TO BECOME SUNOVION PHARMACEUTICALS INC.
May 27, 2010 (PDF/63KB)Corporate

JCR Pharmaceuticals and Dainippon Sumitomo Pharma sign an Assignment Agreement for the growth hormone business
Apr. 26, 2010 (PDF/41KB)Corporate

Announcement of a decision of Supreme Court of Japan about the suit
Jan. 21, 2010 (PDF/63KB)Corporate

JCR Pharmaceuticals and Dainippon Sumitomo Pharma sign a Letter of Intent for the assignment and acceptance of the growth hormone business
Nov. 12, 2009 (PDF/1,573KB)Corporate

Sepracor　Factbook 2009
Oct. 21, 2009 (PDF/35KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. Completes Acquisition of Sepracor Inc.
Oct. 14, 2009 (PDF/45KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. Completes Tender Offer for Sepracor Inc.
Sep. 03, 2009 (PDF/55KB)Corporate

Dainippon Sumitomo Pharma Co., Ltd. to Acquire U.S.-based Sepracor Inc.
Jun. 26, 2009 (PDF/40KB)Corporate

Announcement of establishment of a holding company in the U.S.
Apr. 09, 2009 (PDF/39KB)Corporate

Wakunaga appealed to the Supreme Court against the Osaka High Court's decision
Mar. 24, 2009 (PDF/40KB)Corporate

Announcement of a judgment of the suit (an appeal court decision)
Nov. 26, 2008 (PDF/43KB)Corporate

DSP takes over Kyowa Hakko Kirin's manufacturing subsidiary in China.
Mar. 28, 2008 (PDF/19KB)Corporate

Change of Representative Directors
Apr. 05, 2007 (PDF/50KB)Corporate

Investment in bio-venture fund
Aug. 21, 2006 (PDF/52KB)Corporate

Dainippon Sumitomo Pharma and Sumitomo Chemical agree with Pfizer on Settlement of Amlodin Lawsuit
Jun. 19, 2006 (PDF/15KB)Corporate

English Court denies its jurisdiction over the Amlodin lawsuit brought by Pfizer
May 11, 2006 (PDF/18KB)Corporate

Results of Re-employment Assistance Program
Apr. 26, 2006 (PDF/21KB)Corporate

Notice of Commemorative Dividend
Feb. 24, 2006 (PDF/18KB)Corporate

Implementation of Re-employment Assistance Program
Jan. 25, 2006 (PDF/36KB)Corporate

Pfizer files lawsuit in England regarding licence for Amlodin
Apr. 28, 2005 (PDF/24KB)Corporate

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Finalize Merger Agreement
Nov. 25, 2004 (PDF/34KB)Corporate

Dainippon Pharmaceutical and Sumitomo Pharmaceuticals Enter into a Basic Agreement to Merge on October 1, 2005